This clinical trial is evaluating an investigational treatment that combines an oral medication with non-invasive, low-intensity ultrasound delivered to both sides of the brain, in addition to standard glioblastoma treatment.
Timing matters. If you have been newly diagnosed with Butterfly GBM and have not yet started radiation and temozolomide, contact us now to see if you may be eligible.
ABOUT BUTTERFLY GBM
Butterfly GBM is a pattern of glioblastoma in which the tumor crosses the brain’s midline and extends into both cerebral hemispheres, most commonly through a structure called the corpus callosum.
Because the tumor involves both sides of the brain, it can be difficult to treat with surgery alone. Many clinical trials for newly diagnosed GBM exclude patients with this Butterfly pattern, leaving fewer research options.
This study was designed specifically for people with newly diagnosed Butterfly GBM.
Case courtesy of Frank Gaillard, Radiopaedia.org, rID: 2589
ABOUT THE TRIAL
This Phase 1 clinical trial is studying an investigational treatment for adults with newly diagnosed Butterfly GBM. The treatment combines an oral medication with low-intensity ultrasound delivered through a specialized treatment system.
The study is designed to evaluate safety and tolerability and also to look for signs of anti-tumor activity, including tumor response and overall survival.
The investigational treatment is added to standard glioblastoma care. Participants still receive standard radiation and temozolomide.
How it works
Recently diagnosed? Please contact us as soon as possible. Under the current study design, the first investigational treatment must occur before standard radiation and temozolomide begin. If your treatment is already scheduled but has not started, you may still have time to be evaluated.
If you have questions about the Butterfly GBM clinical trial, a team member can speak with you after the initial screening.
If you are unsure whether the tumor has a Butterfly pattern, you may still complete the qualification check. The clinical team can help determine whether the study may be appropriate after reviewing the available information.
